At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 742 enrolled
Drug / intervention
Symbicort Turbuhaler +2 moredrug
Likely dose
Symbicort Turbuhaler 4.5 μgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 6-week, Phase III, Double-blind, Randomized, Multi-centre, Parallel-group Study Evaluating the Efficacy and Safety of 2 Actuations Symbicort®pMDI® 40/2.25 μg Twice Daily Compared With 1 Inhalation Symbicort Turbuhaler® 80/4.5 μg Twice Daily and 1 Inhalation Pulmicort®Turbuhaler® 100 μg Twice Daily
In Brief
A Phase 3 clinical trial evaluating Symbicort Turbuhaler, Symbicort pMDI, and 1 other intervention for Bronchial Asthma. Completed, enrolled 742 participants across 48 sites in 4 countries.
Detailed Summary
The purpose of the this study is to evaluate the efficacy and safety of 2 actuations Symbicort®pMDI® 40/2.25 μg twice daily compared with1 inhalation Symbicort Turbuhaler® 80/4.5 μg twice daily and 1 inhalation Pulmicort®Turbuhaler® 100 μg twice daily for 6 weeks.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBronchial Asthma
CountriesBulgaria, Czechia, Hungary, Poland
Collaborators--
Timeline
Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartSep 2007
First PostedSep 2007
Primary CompletionApr 2008
TodayJul 2026
First PostedSep 28, 2007
Enrollment StartSep 1, 2007
Primary CompletionApr 1, 2008
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 18.8 years ago
Interventions
Symbicort Turbuhalerdrug
Symbicort Turbuhaler® 80/4.5 μg 1 Inhalation Twice Daily
Symbicort pMDIdrug
Symbicort®pMDI® 40/2.25 μg 2 Actuations Twice Daily
Pulmicort Turbuhalerdrug
Pulmicort®Turbuhaler® 100 μg 1 Inhalation Twice Daily